Venetoclax is a first-in class selective Bcl-2 inhibitor with demonstrated clinical activity in MCL, in particular in combination with Ibrutinib (Davids et al., 2017; Tam et al., 2018). This evidence concerns the gene BCL2 and mantle cell lymphoma.